James Edgemond, serving as both Chief Financial Officer and Treasurer at United Therapeutics Corp (NASDAQ:UTHR), finalized a transaction on June 11, 2026, involving the sale of 10,000 shares of the company's common stock. The total value realized from this sale was $5,492,893. The shares were divested at prices fluctuating between $542.9374 and $551.825 per share. This divestment activity follows a strong performance trajectory for the stock, which has generated a 91% return over the trailing twelve months. At the time of the transaction, UTHR was trading at $545.96, reflecting a market capitalization of $23.1 billion.
The sale was executed in conjunction with the acquisition of 10,000 shares through the exercise of stock options. The exercise price for these options was set at $117.76 per share, resulting in a total exercise cost of $1,177,600. Edgemond confirmed that both the option exercise and the subsequent sale were conducted pursuant to a Rule 10b5-1 trading plan. This pre-arranged framework was established by the executive on October 31, 2025, designed to facilitate trading in compliance with securities regulations.
Following the completion of these transactions, Edgemond's direct holdings in United Therapeutics common stock stand at 18,876 shares. The executive's activity takes place within a corporate environment characterized by robust profitability metrics. United Therapeutics currently reports a gross profit margin of 87% and a price-to-earnings (P/E) ratio of 20. Despite these fundamental strengths, valuation analysis suggests the stock may be trading above its fair value, indicating potential overvaluation relative to intrinsic metrics.
Financial performance data for the first quarter of 2026 presents a mixed picture. United Therapeutics reported revenue of $781.5 million, which fell short of the consensus estimate of $797.4 million. This miss was partially driven by Tyvaso, the company's key product, which generated $457.5 million in revenue, also missing the expected $478.6 million. Net income for the quarter was recorded at $274.9 million, below the anticipated figure of $320.5 million.
On the clinical front, United Therapeutics announced that its TETON-1 Phase 3 study of nebulized Tyvaso in idiopathic pulmonary fibrosis successfully met its primary endpoint. Results published in the New England Journal of Medicine indicated that Tyvaso preserved lung function and reduced the risk of clinical worsening events. In a separate strategic development, the company partnered with Varda Space Industries to explore microgravity-based pharmaceutical processing. This collaboration aims to utilize Varda's orbital manufacturing platform for processing small molecule medicines targeting rare pulmonary diseases.
Analyst sentiment remains divided following the earnings report. TD Cowen reiterated a Buy rating on United Therapeutics, while BTIG maintained a Neutral rating in light of the earnings miss. The company's stock continues to trade actively, with recent data showing a closing price of $545.96, reflecting a 0.56% increase during regular trading hours.